Davizim

Davizim

dacomitinib

Manufacturer:

Pfizer
Concise Prescribing Info
Contents
Dacomitinib
Indications/Uses
1st-line treatment in adults w/ locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ epidermal growth factor receptor (EGFR) exon 19 deletion or 21 L858R substitution mutations as detected by an approved validated test.
Dosage/Direction for Use
45 mg once daily until disease progression or unacceptable toxicity occurs. Recommended dose modification for adverse drug reactions Recommended starting dose: 45 mg once daily; 1st dose reduction: 30 mg once daily; 2nd dose reduction: 15 mg once daily. Severe hepatic impairment (Child-Pugh class C) Initially 30 mg once daily, may be increased to 45 mg once daily based on individual safety & tolerability after at least 4 wk of treatment.
Administration
May be taken with or without food: Take at approx the same time each day.
Contraindications
Special Precautions
Assessment of EGFR mutation status. Perform careful assessment of patients w/ acute onset &/or unexplained worsening of pulmonary symptoms to exclude interstitial lung disease/pneumonitis. Permanently discontinue treatment if interstitial lung disease/pneumonitis is confirmed. Risk of diarrhoea, including severe diarrhoea; rash, erythematous & exfoliative skin conditions; increased transaminases (eg, AST, ALT) & hepatotoxicity. Advise patients to use protective clothing & sunscreen before sun exposure. Periodic liver function testing is recommended. Interrupt treatment in patients who develop severe elevated transaminases during therapy. Avoid concomitant use w/ CYP2D6 metabolised medicinal products & proton-pump inhibitors. Not to be taken by patients w/ rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. May affect ability to drive or operate machinery. Women of childbearing potential should use effective contraception during & at least 17 days after completing therapy. Not to be used during pregnancy. Lactation. Childn <18 yr.
Adverse Reactions
Decreased appetite, hypokalaemia; conjunctivitis; diarrhoea, stomatitis, vomiting, nausea; rash, palmar-plantar erythrodysaesthesia syndrome, skin fissures, dry skin, pruritus, nail disorder, alopecia; fatigue, asthenia; increased transaminases, decreased wt. Dehydration; dysgeusia; keratitis; interstitial lung disease; skin exfoliation, hypertrichosis.
Drug Interactions
Increased mean exposure of dextromethorphan; other medicinal products primarily metabolised by CYP2D6. Avoid co-administration of CYP2D6 substrates w/ narrow therapeutic index (eg, procainamide, pimozide, & thioridazine); proton pump inhibitors. Subtherapeutic exposure of drugs w/ active metabolites formed via CYP2D6 eg, codeine & tramadol. Administer Davizim 2 hr before or at least 10 hr after taking a histamine-2 receptor antagonist. May potentially inhibit P-gp activity, BCRP & organic cation transporter 1.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EB07 - dacomitinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Davizim FC tab 15 mg
Packing/Price
1 × 10's
Form
Davizim FC tab 30 mg
Packing/Price
1 × 10's
Form
Davizim FC tab 45 mg
Packing/Price
1 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in